Last reviewed · How we verify

INSULIN GLARGINE HOE 901

Sanofi · FDA-approved active Small molecule

Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and lower blood glucose levels.

Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Generic nameINSULIN GLARGINE HOE 901
SponsorSanofi
Drug classLong-acting basal insulin
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Insulin glargine is a recombinant human insulin analog engineered with modifications to the A and B chains that slow its absorption and extend its duration of action to approximately 24 hours. It binds to the insulin receptor on target tissues (muscle, fat, liver) to facilitate glucose uptake, suppress hepatic glucose production, and promote anabolic effects. This provides steady basal insulin coverage for patients with diabetes mellitus.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: